TITLE

CLINICAL REVIEW. Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus

AUTHOR(S)
Joffe, David
PUB. DATE
August 2010
SOURCE
American Journal of Health-System Pharmacy;8/15/2010, Vol. 67 Issue 16, p1326
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, adverse effects, and place in therapy of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are reviewed. Summary. Liraglutide, the first once-daily human GLP-1 analogue, retains 97% homology with the endogenous hormone and shares its glucose-dependent glucose-lowering action but has a considerably longer half-life that supports once-daily dosing. After promising Phase II study results, the Liraglutide Effect and Action in Diabetes (LEAD) Phase III clinical development program, involving more than 4000 patients worldwide, investigated the efficacy and tolerability of liraglutide 1.2 or 1.8 mg daily (n = 2735) as monotherapy and in combination with various oral antidiabetic drugs. The LEAD studies yielded encouraging results indicating that patients receiving liraglutide could expect to attain glycosylated hemoglobin reductions of about 1--1.5% and fasting plasma glucose reductions of 15--43 mg/dL. Loss of body weight was consistent throughout the studies: when using liraglutide 1.8 mg as monotherapy, patients lost a mean of 2.5 kg over a 52-week period. Accompanying reductions in some cardiovascular risk endpoints, such as systolic blood pressure, were also observed. By virtue of its glucose-dependent mode of action, liraglutide was generally well tolerated in clinical trials, with only very rare episodes of major hypoglycemia reported. The most frequently observed adverse effects were gastrointestinal, with 10--40% of patients experiencing an episode of nausea, which was often mild or moderate in severity and transient in nature. Conclusion. Liraglutide is efficacious and well tolerated in patients with type 2 diabetes and has been found to reduce weight and blood pressure.
ACCESSION #
52947412

 

Related Articles

  • Understanding the Molecular Dynamics of Type-2 Diabetes Drug Target DPP-4 and its Interaction with Sitagliptin and Inhibitor Diprotin-A. Chakraborty, Chiranjib; Hsu, Minna; Agoramoorthy, Govindasamy // Cell Biochemistry & Biophysics;Nov2014, Vol. 70 Issue 2, p907 

    The occurrence of type 2 diabetes (T2D) accounts for 90-95 % of all diabetes. Intestine hormone glucagon-like peptide-1 (GLP-1) has an antidiabetic role that enhances insulin secretion and pancreatic β-cell proliferation. GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) rapidly....

  • For the Treatment of Type 2 Diabetes, the Vast Majority of Surveyed Physicians in China and South Korea Indicate That There is a Need for GLP-1 Analogues Other Than Byetta.  // Biomedical Market Newsletter;12/21/2011, Vol. 21, p1 

    The article informs that GLP-1 Analogues other than Byetta from Eli Lilly and Co. are needed for the treatment of Type 2 Diabetes. It mentions that the findings are from a survey conducted by Decision Resources in China and South Korea. It further informs that the Chinese endocrinologists...

  • Linagliptin linked to better blood sugar in black patients with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Jun2012, Vol. 10 Issue 6, p17 

    The article focuses on the effectiveness of linagliptin in improving the blood sugar levels of African American patients with type 2 diabetes, as discussed by researcher James Thrasher at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress...

  • GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus. Legakis, Ioannis // Recent Patents on Endocrine, Metabolic & Immune Drug Discovery;Nov2007, Vol. 1 Issue 3, p193 

    The gastrointestinal tract has a crucial role in the control of energy homeostasis through the action of multiple peptides known as incretins that act on distant target sites to promote the efficient uptake and storage of energy. In particular, GLP-1, an incretin hormone secreted from the...

  • This month: Dumping Dependent Diabetes: Surgical Paradigm. Martinez, Tracy // Bariatric Times;Nov2013, Vol. 10 Issue 11, p12 

    The article focuses on a research on surgical treatment methods for type two diabetes (T2D). Topics discussed include the approach of scientists on Billroth-2 and Roux-en-Y operations, postgastrectomy syndrome, and importance of glucagon like peptide-1 hormone in the treatment. It mentions that...

  • Liraglutide LEADing the way in the former Eastern Bloc. Summers, Leanne // PharmacoEconomics & Outcomes News;11/27/2010, Issue 617, p7 

    The article presents several studies presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Prague, Czech Republic, which examined the cost effectiveness of liraglutide in patients with type 2 diabetes mellitus (T2DM) in...

  • Ileal Effect on Blood Glucose, HbA1c, and GLP-1 in Goto-Kakizaki Rats. Buchwald, Henry; Menchaca, Hector; Michalek, Van; Bertin, Nestor // Obesity Surgery;Nov2014, Vol. 24 Issue 11, p1954 

    Background: There have been enumerable studies on the effects of glucagon-like peptide-1 (GLP-1) on satiety and pancreatic islet function, stimulating the advocacy of surgical transposition of the ileum (rich in GLP-1-generating L-cells) higher in the gastrointestinal tract for earlier...

  • Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. Probstfield, Jeffrey L. // Diabetes Care;Aug2015, Vol. 38 Issue 8, p1558 

    OBJECTIVE Glycemic variability may contribute to adverse medical outcomes of type 2 diabetes, but prior therapies have had limited success in controlling glycemic fluctuations, and the hypothesis has not been adequately tested. RESEARCH DESIGN AND METHODS People with insulin-requiring type 2...

  • BYDUREON(tm) Receives Marketing Authorization in Europe.  // Biomedical Market Newsletter;6/30/2011, p660 

    The article reports on the grant from the European Commission regarding the marketing authorization for Bydureon in Europe. It notes that Bydureon is a glucagon-like peptide-1 (GLP-1) receptor agonist that is said to treat type 2 diabetes as it delivers glycemic control in a single weekly dose....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics